|
Market Closed -
NYSE
04:00:02 28/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 50.94 USD | -0.31% |
|
+0.61% | +3.87% |
| 01:01am | HSBC weighs on FTSE 100 ahead of budget, Fed call | AN |
| 12:50am | GSK plc Presents at 2026 European Society for Medical Oncology Annual Congress, Oct-27-2026 03:30 PM |
Company Valuation: GSK plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 80,458 | 58,381 | 59,112 | 54,944 | 73,201 | 76,734 | - | - |
| Change | - | -27.44% | 1.25% | -7.05% | 33.23% | 4.83% | - | - |
| Enterprise Value (EV) 1 | 100,296 | 75,578 | 74,152 | 68,039 | 87,654 | 97,839 | 95,028 | 92,201 |
| Change | - | -24.65% | -1.89% | -8.24% | 28.83% | 11.62% | -2.87% | -2.97% |
| P/E | 18.6x | 3.93x | 11.9x | 21.3x | 12.9x | 14.2x | 12.2x | 11.4x |
| PBR | 5.34x | 5.47x | 4.4x | 4.02x | 4.51x | 4.8x | 4.24x | 3.66x |
| PEG | - | 0x | -0.2x | -0.4x | 0x | -3.18x | 0.7x | 1.6x |
| Capitalization / Revenue | 2.36x | 1.99x | 1.95x | 1.75x | 2.24x | 2.26x | 2.16x | 2.09x |
| EV / Revenue | 2.94x | 2.58x | 2.45x | 2.17x | 2.68x | 2.89x | 2.68x | 2.51x |
| EV / EBITDA | 8.85x | 7.23x | 6.37x | 6.36x | 7.77x | 8.52x | 7.74x | 7.3x |
| EV / EBIT | 11.4x | 9.27x | 8.44x | 7.44x | 8.96x | 9.45x | 8.56x | 7.95x |
| EV / FCF | 22.6x | 12.1x | 13.6x | 13x | 13.7x | 18.7x | 17.8x | 14.3x |
| FCF Yield | 4.42% | 8.28% | 7.36% | 7.67% | 7.32% | 5.36% | 5.61% | 6.98% |
| Dividend per Share 2 | 1 | 0.6125 | 0.58 | 0.61 | 0.66 | 0.6945 | 0.7471 | 0.7819 |
| Rate of return | 4.98% | 4.26% | 4% | 4.53% | 3.62% | 3.63% | 3.9% | 4.08% |
| EPS 2 | 1.082 | 3.662 | 1.216 | 0.632 | 1.411 | 1.348 | 1.57 | 1.683 |
| Distribution rate | 92.4% | 16.7% | 47.7% | 96.5% | 46.8% | 51.5% | 47.6% | 46.5% |
| Net sales 1 | 34,114 | 29,324 | 30,328 | 31,376 | 32,667 | 33,896 | 35,509 | 36,682 |
| EBITDA 1 | 11,330 | 10,449 | 11,635 | 10,693 | 11,278 | 11,486 | 12,281 | 12,629 |
| EBIT 1 | 8,806 | 8,151 | 8,786 | 9,148 | 9,783 | 10,353 | 11,101 | 11,595 |
| Net income 1 | 4,385 | 14,956 | 4,928 | 2,575 | 5,716 | 5,487 | 6,225 | 6,686 |
| Net Debt 1 | 19,838 | 17,197 | 15,040 | 13,095 | 14,453 | 21,104 | 18,294 | 15,467 |
| Reference price 2 | 20.08 | 14.38 | 14.50 | 13.46 | 18.24 | 19.15 | 19.15 | 19.15 |
| Nbr of stocks (in thousands) | 4,006,383 | 4,060,999 | 4,076,145 | 4,080,519 | 4,012,126 | 4,007,011 | - | - |
| Announcement Date | 9/2/22 | 1/2/23 | 31/1/24 | 5/2/25 | 4/2/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 37.58x | 13.15x | 27.92x | 0.53% | 1,140B | |
| 38.98x | 6.55x | 18.43x | 2% | 641B | |
| 37.5x | 8.41x | 17.39x | 2.4% | 507B | |
| 21.33x | 5.19x | 12.91x | 2.53% | 383B | |
| 102.5x | 5.75x | 24.67x | 2.42% | 347B | |
| 21.61x | 5.64x | 13.85x | 2.84% | 293B | |
| 22.44x | 4.53x | 12.94x | 1.95% | 266B | |
| 28.21x | 7.23x | 12.94x | 2.27% | 240B | |
| -46.25x | 7.08x | 27.47x | 2.08% | 197B | |
| Average | 29.32x | 7.06x | 18.73x | 2.11% | 445.98B | |
| Weighted average by Cap. | 35.01x | 8.33x | 20.42x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GSK Stock
- GSK Stock
- Valuation GSK plc
Select your edition
All financial news and data tailored to specific country editions
